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Protein kinase G (PKG) plays an important role in the
regulation of vascular smooth cell contractility and is
a critical mediator of nitric oxide signaling, which
regulates cardiovascular homeostasis. PKG-I–knock-
out (Prkg1/) mice exhibit impaired nitric oxide/
cGMP-dependent vasorelaxation and systemic hyper-
tension. However, it remains unknown whether
PKG-I deficiency induces pulmonary hypertension. In
this study, we characterized the hypertensive pulmo-
nary phenotypes in Prkg1/ mice and delineated
the underlying molecular basis. We observed a signif-
icant increase in right ventricular systolic pressure in
Prkg1/ mice in the absence of systemic hyperten-
sion and left-sided heart dysfunction. In addition, we
observed marked muscularization of distal pulmonary
vessels in Prkg1/ mice. Microangiography revealed
impaired integrity of the pulmonary vasculature in
Prkg1/ mice. Mechanistically, PKG-I–mediated phos-
phorylation of Rho A Ser188 was markedly decreased,
and the resultant Rho A activation was significantly in-
creased in Prkg1/ lung tissues, which resulted in Rho
kinase activation. The i.t. administration of fasudil, a
Rho kinase inhibitor, reversed the hypertensive pulmo-
nary phenotype in Prkg1/ mice. Taken together,
these data show that PKG-I deficiency induces pulmo-
nary hypertension through Rho A/Rho kinase activa-
tion–mediated vasoconstriction and pulmonary
vascular remodeling. (Am J Pathol 2012, 180:2268–2275;
http://dx.doi.org/10.1016/j.ajpath.2012.02.016)
2268Pulmonary hypertension (PH), characterized by progres-
sive increases in pulmonary vascular resistance and vas-
cular remodeling, causes right-sided heart failure and
mortality without treatment.1,2 Increased pulmonary vas-
cular tone and severe structural remodeling of distal pul-
monary vasculature are primary determinants of in-
creased pulmonary vascular resistance. Because the
molecular mechanisms responsible for pulmonary vascu-
lar remodeling and vasoconstriction remain elusive, there
are limited options available for the prevention and treat-
ment of progressive PH.3,4
Protein kinase G (PKG), a serine/threonine kinase,
plays an important role in the regulation of vascular
smooth cell contractility.5,6 Activation of soluble guanylyl
cyclase by nitric oxide (NO) leads to increased synthesis
of cGMP and activation of PKG. The PKG activation re-
sults in vasorelaxation via several mechanisms, including
lowering of intracellular free Ca2 levels and desensitiza-
tion of the contractile apparatus to Ca2.7,8 Two mam-
malian Prkg genes have been identified, encoding PKG-I
and PKG-II.9 PKG-I is the prevalent PKG isoform ex-
pressed in the cardiovascular system, with a greater level
in smooth muscle cells (SMCs) and a lower level in en-
dothelial cells.10,11 The N-terminus (the first 90 to 100
residues) of PKG-I is encoded by two alternative exons
generating two isoforms: PKG-I and PKG-I.9 The en-
zyme is activated at submicromolar to micromolar con-
centrations of cGMP. The PKG-I is composed of three
functional domains: an N-terminal domain, a regulatory
domain, and a catalytic domain. The regulatory domain
contains two cGMP-binding sites with high and low affin-
ity. The catalytic domain contains the Mg-ATP– and pep-
tide-binding pockets. Binding of cGMP to the regulatory
domain releases the inhibition of the catalytic center by
the N-terminal autoinhibitory/pseudosubstrate site and al-
lows the phosphorylation of serine/threonine residues in
target proteins.6,12 The PKG-I phosphorylates Rho A at
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thereby, prevents activation of its downstream targets,
such as Rho kinase.13,14 Rho kinase–mediated phos-
phorylation of human myosin phosphatase target subunit
1 at Thr696 (corresponding to Thr694 in mouse) inhibits
smooth muscle myosin phosphatase activity and induces
SMC contraction.15
PKG-I–knockout (Prkg1/) mice exhibit impaired NO/
cGMP-dependent vasorelaxation and systemic hyperten-
sion in their early life.16–20 These mutant mice also exhibit
a decreased life span (50% of these mice die before the
age of 5 to 6 weeks),17 diminished ischemia-induced
angiogenesis,21 and disturbed platelet adhesion and ac-
tivation.22 Overexpression of PKG-I increases the sensi-
tivity of cultured vascular SMCs to the anti-proliferative
and pro-apoptotic effects of NO/cGMP,23 whereas down-
regulation of PKG-I induces the change of the SMC phe-
notype from a contractile, differentiated to a synthetic,
dedifferentiated state,24,25 an underlying feature of pul-
monary vascular remodeling. Although PKG dysfunction
has been indicated in the pathogenesis of PH, there is no
genetic evidence demonstrating that PKG-I deficiency
induces PH. Herein, we report that deletion of Prkg1 in-
duces vascular remodeling and vasoconstriction and,
thereby, PH in mice.
Materials and Methods
Mice
All mice were bred and maintained at the University of
Illinois at Chicago facility, according to NIH guidelines.
The generation of Prkg1/ mice by homologous recom-
bination has been described previously.17 Prkg1/mice
were obtained from Dr. Xiaoping Du (University of Illinois
College of Medicine). Littermates of Prkg1/ and WT
mice in C57BL/6 background were used. Approval for
animal care and use in these experiments was granted
by the Animal Care and Use Committee.
Primary Cultures of Mouse Pulmonary SMCs
Primary cultures of mouse lung SMCs from wild-type (WT)
or Prkg1/ mice were isolated as previously de-
scribed.26 Briefly, a 21-gauge needle was inserted into
the right ventricle to perfuse the pulmonary circulation
with hot HBSS (50°C) and then with 2-m irons in 0.5%
agarose. The lung was then dissected, minced, and col-
lected in a 15-mL tube. After incubation with collagenase
A (1 mg/mL in HBSS; Roche Applied Sciences, Indianap-
olis, IN) at 37°C for 45 minutes with shaking, the rosetted
cells were isolated and washed using a magnetic particle
concentrator (Dynal MPC-15; Dynal, Oslo, Norway). The
freshly dispersed SMCs were plated onto a 60-mm cell
culture dish and incubated with Dulbecco’s modified Ea-
gle’s medium containing 10% newborn calf serum, pen-
icillin (100 U/mL), and streptomycin (100 g/mL) in a
humidified atmosphere of 5% CO2 in air at 37°C and
grown to 90% to 95% confluence. These primary SMCs
were used at passage 2 for all experiments.Hemodynamic Measurements
Right ventricular systolic pressure (RVSP) was deter-
mined with a 1.4F pressure transducer catheter (Millar
Instruments, Houston, TX) and AcqKnowledge software
(Biopac Systems Inc., Goleta, CA), as previously de-
scribed.26 Briefly, the 1.4F pressure transducer was in-
serted through the right external jugular vein of anesthetized
mice (100 mg ketamine/5 mg xylazine/kg body weight, i.p.)
and threaded into the right ventricle. RVSP was then re-
corded and analyzed with AcqKnowledge software. To in-
hibit Rho kinase, fasudil (60 mmol/L in 25 L of saline) was
administered into each mouse through tracheal instillation.
RVSP was monitored continuously for 30 minutes after ad-
ministration of fasudil. Carotid artery pressure was also de-
termined with a 1.4F pressure transducer catheter.
Echocardiography
Transthoracic two-dimensional targeted M-mode echo-
cardiography was performed with a 15-MHz linear array
transducer attached to a commercially available Sequoia
C256 system (Siemens, Mountain View, CA). Mice were
anesthetized with methoxyflurane (Metofane; Dow Chem-
ical Company, Hawthorn Woods, IL), intubated, and
maintained on isoflurane anesthesia. Images of the left ven-
tricle (LV) were taken from the parasternal short-axis view at
the level of the papillary muscles. Interventricular septal and
LV posterior wall thickness and LV internal dimensions at
the end of diastole and systole weremeasured by the Amer-
ican Society of Echocardiography leading-edge method
from at least three consecutive cardiac cycles on the M-
mode tracings, with a paper speed of 200 mm/second. The
percentage fractional shortening of the LV was calculated
from digital images by subtracting the LV systolic internal
dimension from the LV diastolic internal dimension and di-
viding by the LV diastolic internal dimension.
Fluorescent Microangiography
A 1% low melting point agarose (Sigma-Aldrich, St. Louis,
MO) solution containing 0.2-m yellow-green fluorescent
microspheres was prewarmed and injected into the pul-
monary artery through the left atrial appendage. The
lungs were then fixed in 4% paraformaldehyde in PBS for
48 hours at 4°C, and sections (150 to 200 m thick) were
prepared for imaging. Confocal optical sectioning was used
to produce a Z-stack of images spanning 150 mof section
depth. Projection images were generated from the Z-series
to demonstrate vessel architecture throughout the entire
thickness of the section. Fluorescence intensity was quan-
tified in three separate sections per animal and three rep-
resentative regions per section by a blinded observer. For
this analysis, a single confocal optical section was taken at
a predefined depth (10 m) using fixed gain and power
settings. The perfusion index was calculated as the area
ratio of the image surpassing the threshold value. The per-
fusion index represents the proportion of the optical section
filled by vascular perfusion.27
(loadin
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Lung tissues were fixed for 5 minutes by instillation of
10% PBS–buffered formalin through tracheal catheteriza-
tion at a transpulmonary pressure of 15 cm H2O, and then
overnight at 4°C with agitation.26 After paraffin process-
ing, the tissues were cut into semithin sections (4 to 5 m
thick). For immunofluorescent staining, antigen retrieval
was performed by incubating the slides in 10 mmol/L
sodium citrate (pH 6.0) at 95°C for 10 minutes. After
1-hour incubation at room temperature in a blocking so-
lution containing 2% bovine albumin serum (Sigma-Al-
drich), 0.1% Triton X-100, and 2% normal goat serum, the
sections were incubated for 2 hours at room tempera-
ture with anti– smooth muscle actin (-SMA) mono-
clonal antibody (1:400; Sigma-Aldrich). Nuclei were
counterstained with DAPI. The anti–-SMA–positive
pulmonary arterial vessels per field (original magnifi-
cation, 200) were counted based on the diameter
(40 versus 40 m). Twenty fields per section were
randomly identified and counted.
Western Blot Analysis
Western blot analysis was performed using the following
antibodies: anti-Rho A phosphorylated Ser188 (1:500;
Santa Cruz, Santa Cruz, CA), anti-PKG-I (1:1000; Assay
Designs, Inc. Ann Arbor, MI), anti-vasodilator-stimulated
phosphoprotein (VASP; 1:1000; Axxora, San Diego, CA),
and anti-VASP phosphorylated Ser239 (1:200; Axxora).
Anti--actin (1:4000;BDBiosciences, San Jose,CA)wasused
as a loading control. Signals from immunoreactive bands
were visualized by fluorography using an enhanced
chemiluminescence (ECL) reagent (Thermo Fisher Sci-
entific, Waltham, MA). The intensity of each band was
quantified using NIH ImageJ software (Bethesda, MD).
RhoGTPase Activity Assay
The GTP-bound active forms of Rho A were determined
by pull-down assay.28 Cells were washed with ice-cold
Figure 1. PKG-I deficiency induces PH in Prkg1/mice. Representative RV
mice. RVSP was measured in age- and sex-matched 7- to 8-week-old mice. D
analysis of PKG-I expression and phosphorylation of VASP in lungs from 7
antibodies against PKG-I, phosphorylated VASP (pVASP), VASP, and -actin
significantly decreased in Prkg1/ lungs compared with WT lungs.PBS five times and lysed in a lysis buffer (50 mmol/L Tris,pH 7.4; 1% Triton X-100; 0.5% sodium deoxycholate;
0.1% SDS; 500 mmol/L NaCl; 10 mmol/L MgCl2; 10
g/mL each of aprotinin and leupeptin; and 1 mmol/L
phenylmethylsulfonyl fluoride). Similarly, lung tissues
were homogenized with the same lysis buffer. After cen-
trifugation at 18,000  g at 4°C for 2 minutes, the
extracts were incubated at 4°C for 60 minutes with
glutathione-Sepharose beads coupled with glutathio-
ne-S-transferase–rhotekin fusion protein for determina-
tion of Rho A activity, following the manufacturer’s in-
structions (Cytoskeleton Inc., Denver, CO). Bound Rho A
proteins were quantified by using Western blot analysis,
as previously described. Total Rho A levels were also
determined by using direct Western blot analysis.
Statistical Analysis
Differences between groups were examined for statistical
significance using the Student’s t-test. P  0.05 was
considered significant.
Results
PKG-I Deficiency Induces PH in Prkg1/ Mice
To determine the consequences of genetic deletion of
Prkg1, we measured RVSP (to reflect the pulmonary ar-
tery systolic pressure) in Prkg1/ mice. Prkg1/ mice
had significantly increased RVSP compared with WT
mice (Figure 1, A–C). Genetic deletion of Prkg1 was con-
firmed using Western blot analysis (Figure 1D). Accord-
ingly, decreased phosphorylation of VASP, a substrate of
PKG-I, was observed in Prkg1/ lungs compared with
WT lungs. These data indicate that PKG-I deficiency in-
duces PH in mice. Because structural remodeling of dis-
tal pulmonary arteries is the underlying feature of pulmo-
nary vascular remodeling in the pathogenesis of PH, we
stained lung sections with anti–-SMA and quantified the
number of muscularized distal pulmonary vessels.
Prkg1/ lungs exhibited a 10-fold increase in muscu-
larized distal arteries (40 m in diameter) compared
gs in WT (A) or Prkg1/mice (B). C:Marked increase of RVSP in Prkg1/
xpressed as mean  SD. *P  0.01 versus WT (n  4 to 6). D: Western blot
ld mice. Lung lysate (30 g per lane) was loaded and immunoblotted with
g control). Consistent with deletion of Prkg1, phosphorylation of VASP wasSP tracin
ata are e
-week-owith WT, whereas a similar number of muscularized large
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WT lungs (Figure 2, A and B).
To assess the integrity of the pulmonary vasculature, we
performed fluorescent microangiography by perfusing the
Figure 3. Impaired pulmonary vascular perfusion in Prkg1/ mice. A:
Representative micrographs of fluorescent microangiography of lung sec-
tions perfused with fluorescent microspheres (green) suspended in agarose.
Normal filling of the microvasculature was observed in WT lungs, whereas
Prkg1/ lungs showed a marked loss of microvascular perfusion and wide-
Figure 2. Increased muscularization of distal pulmonary arteries in
Prkg1/ mice. A: Representative micrographs of immunostaining of WT
and Prkg1/ lung sections from 7-week-old mice with anti–-SMA (red).
Arrows, muscularized distal pulmonary arterial vessels in Prkg1/ lung
sections. B: Quantification of muscularized pulmonary arterial vessels in
mouse lung sections. -SMA–positive vessels were counted in 20 fields
(original magnification, 200) of each lung section. Data are expressed as
mean SD. *P 0.001 versus WT vessels with a diameter40 m (n 4 mice
in each group). Prkg1/ lungs exhibited a 10-fold increase in muscularized
distal arteries (40 m in diameter) compared with WT.spread pre-capillary occlusion. B:Quantification of pulmonary microvascular
perfusion. Data are expressed as mean  SD. *P  0.01 versus WT (n  3).lungs with fluorescent microspheres (green) suspended in
agarose.27 Normal filling of the microvasculature was ob-
served in WT mouse lungs, whereas Prkg1/ lungs
showed a marked loss of microvascular perfusion and
widespread pre-capillary occlusion (Figure 3, A and B).
These data suggest that microvascular remodeling and
pre-capillary occlusion cause impaired pulmonary vascular
integrity in Prkg1/ mice.
PH in Prkg1/ Mice Is Independent of
Left-Sided Heart Disease and Systemic
Hypertension
To determine whether left-sided heart dysfunction is in-
Figure 4. Normal left-sided heart function in Prkg1/ mice. A: Transtho-
racic M-mode echocardiographic tracings in a WT and Prkg1/ mouse
(45-day-old littermate). Double-sided arrows, LV dimensions. EDD, end-
diastolic dimension; ESD, end-systolic dimension; FS, fraction shortening,
indicating cardiac contractility. B: Histological sections of hearts from 45-day-
old littermates. Hearts were fixed in formalin and stained with H&E. Data are
representative of three independent experiments with nearly identical re-
sults. C: Measurement of carotid artery pressure demonstrating no systemic
hypertension in Prkg1/ mice. Data are expressed as mean  SD (n  3).
*P  0.05. CADP, carotid artery diastolic pressure; CASP, carotid artery
systolic pressure; KO, knockout.volved in the pathogenesis of PH in Prkg1/mice, echo-
DD, left
tricular
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evaluate in vivo cardiac function of age-matched litter-
mates. The Prkg1/ mice, at the age of 45 days, exhib-
ited a similar LV function as the WT mice (Figure 4A and
Table 1). There was no evidence of LV hypertrophy and
hypertension in Prkg1/ mice compared with WT mice.
A histological examination of the Prkg1/ heart revealed
similar sizes of ventricular chambers and thickness of the
posterior wall and septum (Figure 4B). Measurement of
carotid artery pressure revealed no systemic hyperten-
sion in Prkg1/ mice at the age of 45 days (Figure 4C).
These data suggest that PH in Prkg1/ mice is not
secondary to LV dysfunction and systemic hypertension.
PKG-I Deficiency Results in Decreased
Phosphorylation of Rho A Ser188 and
Increased Activation of Rho A
Previous pharmacological studies13,29,30 have demon-
strated that PKG phosphorylates Rho A at Ser188 and
subsequently inhibits its membrane association, which
prevents activation of its downstream targets, such as
Rho kinase. To assess whether PKG-I deficiency results
in decreased phosphorylation of Rho A, we performed
Western blot analysis on lung tissues from WT or
Prkg1/ mice using antibody against phosphorylated
Ser188 of Rho A. As shown in Figure 5, A and B, a
marked decrease of phosphorylation of RhoA Ser188 in
Prkg1/ lungs was observed compared with WT lungs.
To determine whether PKG-I deficiency promotes Rho A
membrane association and activation, we performed a
pull-down assay with glutathione-Sepharose beads, cou-
pled with glutathione-S-transferase–rhotekin fusion pro-
tein.28 As shown in Figure 5, C and D, there was a more
than twofold increase in GTP-bound Rho A in Prkg1/
lungs compared with WT lungs, whereas total Rho A
expression was similar in both WT and Prkg1/ lungs,
indicating Rho A activation in Prkg1/ lungs. Rho A
activation was also markedly increased in SMCs isolated
from Prkg1/ lungs compared with WT SMCs (Figure 6,
A and B).
PKG-I Deficiency–Induced Vasoconstriction
through Activation of Rho A–Rho Kinase
Signaling Is a Critical Component of the
Pathogenesis of PH
We next addressed the mechanistic role of PKG-I defi-
Table 1. Analysis of in Vivo Cardiac Size and Function by Echoc
Mouse type LVEDD (mm) LVESD (mm) FS (%)
WT 3.93  0.07 2.84  0.04 28.9  2.
Prkg1/ 3.87  0.05 2.82  0.03 28.5  1.
Data are expressed as the mean  SD (n  3). Echocardiography w
*P  0.05.
BW, body weight; EF, ejection fraction; FS, fractional shortening; LVE
dimension; PWth, left ventricular posterior wall thickness; SEPth, intravenciency–induced activation of Rho A–Rho kinase signalingin the pathogenesis of PH. After measurement of RVSP at
the basal level, the mice were immediately treated with
fasudil, a Rho kinase inhibitor, and RVSP was continu-
ously monitored for an additional 30 minutes. There was
a marked increase of RVSP in Prkg1/ mice compared
with WT mice under basal conditions; however, fasudil
treatment resulted in a significant decrease of RVSP in
Prkg1/ mice but not in WT mice (Figure 7, A–C). These
data suggest that Rho kinase–mediated vasoconstriction
is an important component of the pathogenesis of PH in
Prkg1/ mice.
Discussion
To our knowledge, this is the first study to demonstrate
that genetic disruption of Prkg1 causes PH in mice. Our
data have shown that Prkg1/ lungs exhibit severe pul-
monary vascular remodeling, as evidenced by muscular-
raphy in WT and Prkg1/ Mice
EF (%) SEPth (mm) PWth (mm) BW (g)
56.1  3.5 0.75  0.06 0.75  0.07 24.7  1.5
54.4  2.1 0.73  0.04 0.71  0.03 20.0  0.8*
rmed in anesthetized sex-matched 45-day-old mice.
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic
septal wall thickness.
Figure 5. PKG-I deficiency activates Rho A signaling in Prkg1/ lungs. A:
Western blot analysis demonstrating decreased phosphorylation of Rho A at
Ser188 (pS188-RhoA). Lung lysates, 30 g, from 6-week-old mice per lane
were loaded and immunoblotted with an anti-phosphorylated Ser188 of Rho
A antibody. The experiment was repeated twice with similar data. B: Den-
sitometric analysis of Rho A phosphorylation (p-Rho A) at Ser188. The
intensity of each band of phosphorylated Ser–Rho A was normalized to the
intensity of the respective total Rho A band. Data are expressed as mean 
SD (n  3). *P  0.05 versus WT. C: PKG-I deficiency results in decreased
phosphorylation of Rho A at Ser188. Prominent Rho A activation in Prkg1/
lungs. Lung lysates, 300 g, from 6-week-old WT or Prkg1/ mice were
used for pull-down assays to determine the GTP-bound active RhoA (GTP-
Rho A). Each lung lysate, 30 g, was loaded per lane for detection of total
Rho A with an anti-Rho A antibody. Anti--actin immunoblotting was used as
a loading control.D: Densitometric analysis of Rho A activation. The intensity
of each band of GTP–Rho A was normalized to the intensity of the respective




as perfoWT. Rho A activity in Prkg1 lungs was more than twofold greater than in
WT lungs.
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integrity. PKG-I deficiency results in activation of Rho
A–Rho kinase signaling, which causes vascular remod-
eling and vasoconstriction. Our data demonstrate that
PKG-I deficiency–induced vasoconstriction is the critical
component of the pathogenesis of PH in Prkg1/ mice.
The biological importance of NO/cGMP/PKG signaling
was first appreciated for promoting vascular smooth
muscle relaxation.31,32 NO stimulates cGMP synthesis
and activates PKG in vascular SMCs, thereby relaxing
small arteries and arterioles, resulting in a decreased
blood pressure.33 Prkg1/ mice exhibit defective relax-
ation of vascular, visceral, and penile smooth muscle17–
20; thus, Prkg1/ mice show impaired cGMP-dependent
relaxation of large and small arteries and develop sys-
temic hypertension as early as the age of 4 weeks.17
However, the elevated blood pressure in Prkg1/ mice
is returned to a normal level at an older age (eg, 6 weeks
old).17,34 The normalization of blood pressure in older
Prkg1/ mice may be the result of cross activation of
protein kinase A by the high cGMP levels that are poten-
Figure 6. PKG-I deficiency induces Rho A activation in Prkg1/ pulmo-
nary vascular SMCs. A: Representative Western blot analyses demonstrating
Rho A activation in Prkg1/ pulmonary vascular SMCs. Pulmonary vascular
SMCs isolated from 6-week-old mouse lungs were expanded in culture and
lysed at passage 2 for detection of GTP–Rho A by pull-down assays. Total
Rho A was detected by direct immunoblotting with an anti-Rho A antibody.
-Actin immunoblotting was used as a loading control. B: Densitometric
analysis of Rho A activation. The intensity of each band of GTP–Rho A was
normalized to the intensity of the respective total Rho A band. Data are
expressed as mean SD (n 3 independent experiments). Rho A activity in
Prkg1/ SMCs was threefold greater than in WT SMCs. *P 0.01 versus WT.
Figure 7. The causal role of Rho kinase activation, secondary to PKG-I def
at the basal level and after fasudil treatment in WT (A) and Prkg1/ mice
treated with Rho kinase inhibitor fasudil (60 mmol/L in 25 L of saline/mou
/RVSP in Prkg1 mice after fasudil treatment. Data are expressed as mean  SD (n
at the basal level, and ‡P  0.05 versus WT treated with fasudil.tially generated in these mice.35,36 Herein, we show that
Prkg1/ mice exhibit hypertensive pulmonary pheno-
types at the age of 6 to 8 weeks, independent of systemic
hypertension and LV dysfunction. The persistent hyper-
tensive pulmonary phenotypes suggest that vasorelax-
ation via the cGMP/PKG-I pathway is essential to the
regulation of basal pulmonary vascular pressure, which is
in contrast to its role in regulation of basal blood pres-
sure.17,34 Our recent studies26,37 have also shown that
tyrosine nitration-mediated impairment of PKG-I activity,
secondary to loss of caveolin-1, results in the develop-
ment of PH in Cav1/ mice. Taken together, these data
demonstrate the essential role of normal PKG-I activity in
regulating the pulmonary vascular tone. Impaired PKG
activity, through either decreased expression or post-
translational modification, leads to PH.
Lincoln and colleagues38,39 first described a role for
PKG in modulation of aortic SMC phenotype and impli-
cated its role in vascular disease. They observed that
constitutive expression of PKG-I restores the contractile
phenotype in cultured aortic SMCs, whereas inhibition of
PKG reverses the phenotype.39 Overexpression of PKG-I
increases the sensitivity of cultured vascular SMCs to the
anti-proliferative and pro-apoptotic effects induced by
NO/cGMP,23 whereas down-regulation of PKG-I induces
the change of SMC phenotype from a contractile, differ-
entiated to a synthetic, dedifferentiated state,24 which is
the characteristic feature of pulmonary vascular remod-
eling. We have observed a 10-fold increase of muscu-
larization of distal pulmonary vessels, a drastic loss of
microvascular perfusion, and widespread pre-capillary
occlusion in Prkg1/ lungs. These data suggest that
PKG-I deficiency induces pulmonary microvascular re-
modeling and pre-capillary occlusion, resulting in im-
paired pulmonary vascular integrity, and thereby contrib-
utes to the pathogenesis of PH in Prkg1/ mice.
Recent studies14,40–42 have shown an important role of
the PKG-regulated Rho A/Rho kinase signaling pathway
in modulating pulmonary vascular remodeling and vaso-
constriction. PKG-I phosphorylates Rho A at Ser188 and
in the pathogenesis of PH in Prkg1/ mice. Representative RVSP tracings
r measurement of RVSP under basal conditions, the 7-week-old mice were
and then RVSP was continuously monitored for 30 minutes. C: Normalized
† /iciency,
(B). Afte
se, i.t.), 3 to 5). *P  0.01 versus WT at the basal level, P  0.05 versus Prkg1
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Rho kinase activation.13,15 Consistently, we observed de-
creased phosphorylation of Rho A Ser188 and resultant
activation of Rho A in Prkg1/ lungs. PKG-I deficiency
also leads to marked Rho A activation in primary cultures
of pulmonary vascular SMCs isolated from Prkg1/
lungs. However, the total protein levels of Rho A in
Prkg1/ lungs and isolated pulmonary vascular SMCs
are the same as in WT lungs. In contrast, other studies
have shown a critical role of PKG in mediating NO-stim-
ulated Rho A expression. NO from pulmonary artery
SMCs of rat or human induces Rho A expression via an
increase in Rho A protein stability and Rho A gene tran-
scription through PKG.43 Long-term inhibition of NO syn-
thesis induces a significant decrease in Rho A mRNA and
protein expression in nitro-L-arginine–treated rat aorta
and pulmonary artery.44 Rho A has played a major role in
the regulation of multiple cellular functions, including ac-
tin cytoskeleton organization, contraction, gene expres-
sion, differentiation, and proliferation.14,45–47 Thus, Rho A
activation, secondary to PKG-I deficiency, may be the
major contributor of the severe pulmonary vascular re-
modeling leading to PH in Prkg1/ mice.
We have shown that the Rho A/Rho kinase signaling
pathway plays a key role in the mechanisms of the patho-
genesis of PH in Prkg1/ mice. Short-term inhibition of
Rho kinase by i.t administration of fasudil completely
inhibited the increase of RVSP in Prkg1/ mice. These
data demonstrate that vasoconstriction secondary to im-
pairment of PKG activity is an important component of the
pathogenesis of PH. Several pharmacological studies
have also suggested a role for Rho kinase in the devel-
opment of PH. The i.v. or oral treatment with Rho kinase
inhibitor (Y-27632 or fasudil) normalizes the high pulmo-
nary arterial pressure in chronically hypoxic rats, attenu-
ates the development of chronic hypoxia-induced PH in
mice, and reduces pulmonary arterial lesions in mono-
crotaline-induced PH in rats.40,41,43 Inhaled Y-27362 or
fasudil causes sustained and selective pulmonary vaso-
dilation in monocrotaline-induced PH and in spontaneous
PH in fawn-hooded rats, as well as in chronically hypoxic
rats.48 Rho kinase is one of the main downstream effec-
tors of Rho A. On activation, Rho A activates Rho kinase,
which phosphorylates the myosin phosphatase target
subunit 1 of smooth muscle myosin phosphatase at
Thr696 and leads to inhibition of its activity, an increased
sensitivity of myosin light chain to calcium, and contrac-
tion.15,49 These data collectively suggest that activation
of the Rho A/Rho kinase signaling pathway secondary to
decreased PKG activity is a critical component of the
underlying mechanisms of PH in Prkg1/ mice.
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